Journal of Drug Issues 2005;35(3):529-546.
Joseph R. Guydish, PhD, Sarah Turcotte Manser, MA, Martha A. Jessup, RN, PhD, Barbara M. Tajima, MEd, Clare Sears, MA (previous five all from the University of California San Francisco, CA/AZ Node), Theresa Montini, PhD (National Institutes of Health).
The National Institute on Drug Abuse (NIDA) Clinical Trials Network (CTN) is intended to test promising drug abuse treatment models in multisite clinical trials and to support adoption of new interventions into clinical practice. Using qualitative research methods, the authors asked the following question: How might the technology of multisite clinical trials be modified to better support adoption of tested interventions? A total of 42 participants, representing eight organizational levels ranging from clinic staff to clinical trial leaders, were interviewed about their role in the clinical trial, its interactions with clinics, and intervention adoption. Among eight clinics participating in the clinical trial, the authors found adoption of the tested intervention in one clinic only. Analysis of interview data revealed four conceptual themes likely to affect adoption and may be informative in future multisite clinical trials. Planning for adoption in the early stages of protocol development will better serve the aim of integrating new interventions into practice. (Article (Peer-Reviewed), PDF, English, 2005)
Keywords: Community health services | CTN platform/ancillary study | CTN protocol development | CTN research agenda | Dissemination | Dissemination strategies | Research design | Journal of Drug Issues (journal)
Document No: 179, PMCID: PMC2947142
Submitted by Joseph Guydish, PhD, Institute for Health Policy Studies, UCSF, 3/22/2007.